Computed Tomography-Based Interstitial Brachytherapy for Recurrent Cervical Carcinoma in the Vaginal Apex

Chopra, Supriya; Shukla, Richa; Mahantshetty, Umesh; Phurailatpam, Reena; Ghadi, Yogesh; Gupta, Sudeep; Shrivastava, Shyamkishore

doi:10.1016/j.clon.2021.09.012

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the 18 included studies in our analysis was a multicenter study from Denmark, France, the Netherland, and Vienna [ 5 ]. Besides, the others studies were from 7 countries, with most publications being from the United States of American ( n = 10) [ 11 , 26 – 34 ], followed by the India ( n = 2) [ 12 , 13 ], Austria [ 35 ], Canada [ 3 ], Denmark [ 36 ], France [ 4 ], and Japan [ 37 ] (one each). The main characteristics of the 18 included studies are presented in Tables 1 and 2 .…”

Section: Resultsmentioning

confidence: 99%

Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer

Wang,

Guo,

Zhao

2024

BMC Cancer

View full text Add to dashboard Cite

Objective This study aimed to establish the dose-response relationship between volume base dose and tumor local control for vaginal cancer, including primary vaginal cancer and recurrent gynecologic malignancies in the vagina. Materials and methods We identified studies that reported volume base dose and local control by searching the PubMed, the Web of Science, and the Cochrane Library Database through August 12, 2023. The regression analyses were performed using probit model between volume based dose versus clinical outcomes. Subgroup analyses were performed according to stratification: publication year, country, inclusion time of patients, patients with prior radiotherapy, age, primaries or recurrent, tumor size, concurrent chemoradiotherapy proportion, dose rate, image modality for planning, and interstitial proportion. Results A total of 879 patients with vaginal cancer were identified from 18 studies. Among them, 293 cases were primary vaginal cancer, 573 cases were recurrent cancer in the vagina, and 13 cases were unknown. The probit model showed a significant relationship between the HR-CTV (or CTV) D90 versus the 2-year and 3-year local control, P values were 0.013 and 0.014, respectively. The D90 corresponding to probabilities of 90% 2-year local control were 79.0 GyEQD2,10 (95% CI: 75.3–96.6 GyEQD2,10). Conclusions A significant dependence of 2-year or 3-year local control on HR-CTV (or CTV) D90 was found. Our research findings encourage further validation of the dose-response relationship of radical radiotherapy for vaginal cancer through protocol based multicenter clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer

Wang,

Guo,

Zhao

2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina

Kamrava¹,

Leung²,

Bachand³

et al. 2023

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Salvage radiotherapy for locally recurrent cervical and endometrial carcinoma: clinical outcomes and toxicities

Cong,

Yang,

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background The management of locally recurrent gynecological carcinoma remains a challenge due to the limited availability of data. This study aims to share our institutional experience in using definitive radiotherapy (RT) for the treatment of locally recurrent cervical and endometrial carcinoma. Methods The study retrospectively reviewed 20 patients in our hospital completing salvage 3D image-based HDR brachytherapy, with or without EBRT, for locally recurrent cervical and endometrial carcinoma after surgery. The Kaplan–Meier method was applied to estimate the disease-free survival (DFS) and overall survival (OS). The toxicities were assessed by CTCAEv5. Results During a median observation period of 21 months, the study reported a tumor objective response rate of 95%. The 3-year DFS and OS rates were 89.4% and 90.9%, respectively. The EBRT combined with brachytherapy achieved a median cumulative dose of 88 Gy to CTV D90. 14 patients received concurrent and/or systemic chemotherapy. Two patients suffered locoregional recurrence after salvage treatment, one of whom only received salvage brachytherapy for prior RT history. The analysis identified significant predictors for DFS, including tumor histology and FIGO stage. 5 patients observed acute grade 1–2 rectal (15%) or genitourinary (10%) toxicities. Late toxicities including grade 1–2 rectal bleeding (10%) and grade 2 pelvic fracture (5%) were seen in 3 patients. Conclusions 3D image-guided brachytherapy combined with EBRT shows effective tumor control and acceptable toxicity profile for women with locally recurrent gynecologic cancer. The success in managing vaginal recurrence is notably influenced by histologic subtype and FIGO staging.

show abstract

Computed Tomography-Based Interstitial Brachytherapy for Recurrent Cervical Carcinoma in the Vaginal Apex

Cited by 3 publications

References 24 publications

Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer

Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer

GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina

Salvage radiotherapy for locally recurrent cervical and endometrial carcinoma: clinical outcomes and toxicities

Contact Info

Product

Resources

About